Our research group is focused on risk estimation, treatment and prevention of age-related brain deterioration.
Department of Neurology Research Labs
The Albers Laboratory uses the olfactory system of mice and humans to explore early pathologic events of neurodegeneration.
We take a multidisciplinary, basic science to clinic translational approach to designing patient-oriented experimental and clinical trials for aging, dementia, and other neurodegenerative disorders.
Borrowing from successes in cancer drug development, the Healey Center and NEALS faculty are leading the first ALS Platform Trial.
Brian Bacskai's laboratory uses sophisticated optical techniques to address fundamental questions in Alzheimer's disease research.
The Badr lab is focused on studying the genetic drivers of malignancy and treatment resistance as well as developing targeted and experimental therapeutics for brain tumors.
The research goal of Dr. Oksana Berezovska's lab is to study the cellular and molecular mechanisms of Alzheimer's disease pathology.
The Bragg Lab combines gene expression profiling and chemical screening of novel cellular models to understand the pathogenesis of hereditary dystonias.
The Breakefield laboratory uses molecular genetic techniques to understand the cause of inherited neurological diseases and to develop vectors which can deliver genes to the nervous system for therapeutic purposes.
The Mass General Center for Rare Neurological Diseases (CRND) aims to eradicate rare disorders of the nervous system by leveraging the power of biological insights towards design and implementation of clinical trials.
Transforming Medicine Through Innovation
Research at Massachusetts General Hospital integrates the full spectrum of "bench to bedside" discovery. Laboratory scientists work collaboratively with clinicians to make discoveries and turn them into treatments, diagnostics and devices that improve our quality of life.